Spotlight on Trastuzumab in Metastatic Breast Cancer Overexpressing HER2

By McKeage K.   Perry C.M.  

American Journal of Cancer, Vol. 1, Iss. 3, 2002-03 ,pp. : 217-221

Adis International

Access to resources Recommend Favorite

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

By Hurvitz Sara   Dalenc Florence   Campone Mario   O’Regan Ruth   Tjan-Heijnen Vivianne   Gligorov Joseph   Llombart Antonio   Jhangiani Haresh   Mirshahidi Hamid   Tan-Chiu Elizabeth   Miao Sara   El-Hashimy Mona   Lincy Jeremie   Taran Tetiana   Soria Jean-Charles   Sahmoud Tarek   André Fabrice  

Breast Cancer Research and Treatment, Vol. 141, Iss. 3, 2013-10 ,pp. : 437-446

Springer Publishing Company

Access to resources Recommend Favorite

Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study

By Sawaki Masataka  

Breast Cancer, Vol. 19, Iss. 3, 2012-07 ,pp. : 253-258

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells with Primary Trastuzumab Resistance

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 12, Iss. 2, 2012-02 ,pp. : 151-162

Bentham Science Publishers

Access to resources Recommend Favorite

Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series

By Rodrigues M. J.   Peron J.   Frnel J.-S.   Vano Y.-A.   Wassermann J.   Debled M.   Picaud F.   Albiges L.   Vincent-Salomon A.   Cottu P. H.  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 916-924

Oxford University Press

Access to resources Recommend Favorite